A year of unprecedented progress in Down syndrome basic research.
The years 2006 and 2007 saw the publication of three new and different approaches to prevention or amelioration of Down syndrome effects on the brain and cognition. We describe the animal model systems that were critical to this progress, review these independent breakthrough studies, and discuss the implications for therapeutic approaches suggested by each.
Reeves
Roger H
RH
Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. rreeves@jhmi.edu
Garner
Craig C
CC
D000818:Animals; D035843:Biomedical Research; D001921:Brain / Q000196:embryology / Q000503:physiopathology; D002891:Chromosomes, Human, Pair 21; D003071:Cognition / Q000187:drug effects; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000523:psychology; D018756:GABA Antagonists / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists; D006801:Humans; D051379:Mice; D009474:Neurons / Q000502:physiology; D011963:Receptors, GABA-A / Q000378:metabolism; D013569:Synapses / Q000502:physiology
D018756:GABA Antagonists; D058787:GABA-A Receptor Antagonists; D011963:Receptors, GABA-A